What We're Reading: Page 132
Industry reads hand-picked by our editors
Jul 05, 2022
-
The Financial Times
Covid vaccines: how can immune imprinting help experts to rethink jabs?
-
STAT
VC deals and valuations begin falling apart amid biotech’s stock shock
-
BioCentury
After Forty Seven takeout, MacQuitty finding ‘freedom’ with Lightspeed team
-
Bloomberg
GSK’s New Vaccine Hire Looks Beyond Covid in Quest for Next Hit
Jul 01, 2022
Jun 30, 2022
-
The Boston Globe
Bayer AG opens Kendall Square research center focused on cancer
-
Science
Bad news for Paxlovid? Coronavirus can find multiple ways to evade COVID-19 drug
-
The New York Times
Behind the Scenes, McKinsey Guided Companies at the Center of the Opioid Crisis
-
Nature
China’s first mRNA vaccine is close — will that solve its COVID woes?
Jun 29, 2022
-
The Atlantic
This Fall Will Be a Vaccination Reboot
-
The Wall Street Journal
U.S. Supply of Effective Covid Antibody Drug Dwindling
-
The New York Times
As Monkeypox Spreads, U.S. Plans a Vaccination Campaign
-
Endpoints News
Sanofi to cut insulin prices for uninsured from $99 to $35, matching the insulin cap coming through Congress
Jun 28, 2022
Jun 27, 2022
Jun 24, 2022
-
The Wall Street Journal
Merck Pushes Forward With Potential Deal for Seagen
-
Bloomberg
Covid Vaccines Prevented 20 Million Deaths in First Year, Study Finds
-
Reuters
Roche sceptical about investing more in 'guided-missile' ADC cancer drugs
-
Biotech Strategy Blog
An alternate perspective on TIGIT
Previous
